Literature DB >> 28114277

The novel MKL target gene myoferlin modulates expansion and senescence of hepatocellular carcinoma.

C Hermanns1, V Hampl1, K Holzer2, A Aigner3, J Penkava1, N Frank1, D E Martin4, K C Maier4, N Waldburger2, S Roessler2, M Goppelt-Struebe5, I Akrap6, A Thavamani6, S Singer2, A Nordheim6,7, T Gudermann1, S Muehlich1.   

Abstract

Megakaryoblastic Leukemia 1 and 2 (MKL1/2) are transcriptional coactivators of Serum Response Factor (SRF) with an essential role for hepatocellular carcinoma (HCC) growth and oncogene-induced senescence. In this report, we identified myoferlin as a novel MKL/SRF target gene by gene expression profiling and verification in vivo in HCC xenografts. Myoferlin was overexpressed in human and murine HCCs triggered by conditional expression of constitutively active SRF-VP16 protein in hepatocytes. Furthermore, myoferlin was required for HCC cell invasion, proliferation and anchorage-independent cell growth. We provide evidence that myoferlin is a crucial gene target of MKL1/2 mediating its effect on oncogene-induced senescence by modulating the activation state of the EGFR and downstream MAPK and p16-/Rb pathways. Depletion of myoferlin in tumour cells from SRF-VP16-derived murine HCCs induced a senescence phenotype. These findings identify MKL1/2 and myoferlin as novel therapeutic targets to treat human HCC by a senescence-inducing strategy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28114277     DOI: 10.1038/onc.2016.496

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

1.  Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.

Authors:  Jun Sang Bae; Sang Jae Noh; Kyoung Min Kim; Kyu Yun Jang; Myoung Ja Chung; Dae Gohn Kim; Woo Sung Moon
Journal:  Int J Oncol       Date:  2013-10-30       Impact factor: 5.650

2.  The role of serum response factor in hepatocellular carcinoma: implications for disease progression.

Authors:  Chang Young Kwon; Kyung Ryoul Kim; Ha Na Choi; Myoung Ja Chung; Sang Jae Noh; Dae Ghon Kim; Myoung Jae Kang; Dong Geun Lee; Woo Sung Moon
Journal:  Int J Oncol       Date:  2010-10       Impact factor: 5.650

3.  A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.

Authors:  Stephanie Roessler; Hu-Liang Jia; Anuradha Budhu; Marshonna Forgues; Qing-Hai Ye; Ju-Seog Lee; Snorri S Thorgeirsson; Zhongtang Sun; Zhao-You Tang; Lun-Xiu Qin; Xin Wei Wang
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

Review 4.  Linking actin dynamics and gene transcription to drive cellular motile functions.

Authors:  Eric N Olson; Alfred Nordheim
Journal:  Nat Rev Mol Cell Biol       Date:  2010-05       Impact factor: 94.444

5.  Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.

Authors:  Sabrina Höbel; Ivette Koburger; Matthias John; Frank Czubayko; Philipp Hadwiger; Hans-Peter Vornlocher; Achim Aigner
Journal:  J Gene Med       Date:  2010-03       Impact factor: 4.565

6.  Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes.

Authors:  Bo Cen; Ahalya Selvaraj; Rebecca C Burgess; Johann K Hitzler; Zhigui Ma; Stephan W Morris; Ron Prywes
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

7.  Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL.

Authors:  Maria K Vartiainen; Sebastian Guettler; Banafshe Larijani; Richard Treisman
Journal:  Science       Date:  2007-06-22       Impact factor: 47.728

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.

Authors:  Shoumei Bai; Mohd W Nasser; Bo Wang; Shu-Hao Hsu; Jharna Datta; Huban Kutay; Arti Yadav; Gerard Nuovo; Pawan Kumar; Kalpana Ghoshal
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

10.  Rho-actin signaling to the MRTF coactivators dominates the immediate transcriptional response to serum in fibroblasts.

Authors:  Cyril Esnault; Aengus Stewart; Francesco Gualdrini; Phil East; Stuart Horswell; Nik Matthews; Richard Treisman
Journal:  Genes Dev       Date:  2014-04-14       Impact factor: 11.361

View more
  17 in total

1.  Inhibition of TRPM7 blocks MRTF/SRF-dependent transcriptional and tumorigenic activity.

Authors:  Thomas Gudermann; Susanne Muehlich; Sandra Voringer; Laura Schreyer; Wiebke Nadolni; Melanie A Meier; Katharina Woerther; Constanze Mittermeier; Silvia Ferioli; Stephan Singer; Kerstin Holzer; Susanna Zierler; Vladimir Chubanov; Bernhard Liebl
Journal:  Oncogene       Date:  2019-12-16       Impact factor: 9.867

2.  Structural Basis for the Distinct Membrane Binding Activity of the Homologous C2A Domains of Myoferlin and Dysferlin.

Authors:  Faraz M Harsini; Anthony A Bui; Anne M Rice; Sukanya Chebrolu; Kerry L Fuson; Andrei Turtoi; Mazdak Bradberry; Edwin R Chapman; R Bryan Sutton
Journal:  J Mol Biol       Date:  2019-04-18       Impact factor: 5.469

3.  Correlation between myoferlin expression and lymph node metastasis in papillary thyroid carcinoma.

Authors:  Ji Min Na; Dong Chul Kim; Dae Hyun Song; Hyo Jung An; Hyun Min Koh; Jeong-Hee Lee; Jong Sil Lee; Jung Wook Yang; Min Hye Kim
Journal:  J Pathol Transl Med       Date:  2022-05-11

4.  PINCH-1 interacts with myoferlin to promote breast cancer progression and metastasis.

Authors:  Tao Qian; Chengmin Liu; Yanyan Ding; Chen Guo; Renwei Cai; Xiaoxia Wang; Rong Wang; Kuo Zhang; Li Zhou; Yi Deng; Chuanyue Wu; Ying Sun
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

5.  Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis.

Authors:  Gilles Rademaker; Brunella Costanza; Justine Bellier; Michael Herfs; Raphaël Peiffer; Ferman Agirman; Naïma Maloujahmoum; Yvette Habraken; Philippe Delvenne; Akeila Bellahcène; Vincent Castronovo; Olivier Peulen
Journal:  Oncogenesis       Date:  2019-03-08       Impact factor: 7.485

Review 6.  Ferlin Overview: From Membrane to Cancer Biology.

Authors:  Olivier Peulen; Gilles Rademaker; Sandy Anania; Andrei Turtoi; Akeila Bellahcène; Vincent Castronovo
Journal:  Cells       Date:  2019-08-22       Impact factor: 6.600

Review 7.  Myoferlin, a multifunctional protein in normal cells, has novel and key roles in various cancers.

Authors:  Wei Zhu; Bolun Zhou; Chenxuan Zhao; Zhengqing Ba; Hongjuan Xu; Xuejun Yan; Weidong Liu; Bin Zhu; Lei Wang; Caiping Ren
Journal:  J Cell Mol Med       Date:  2019-09-01       Impact factor: 5.310

8.  Myoferlin regulates epithelial cancer cell plasticity and migration through autocrine TGF-β1 signaling.

Authors:  Victoria R Barnhouse; Jessica L Weist; Vasudha C Shukla; Samir N Ghadiali; Douglas A Kniss; Jennifer L Leight
Journal:  Oncotarget       Date:  2018-04-10

Review 9.  Myoferlin, a Membrane Protein with Emerging Oncogenic Roles.

Authors:  Yimin Dong; Honglei Kang; Huiyong Liu; Jia Wang; Qian Guo; Chao Song; Yunlong Sun; Ya Zhang; Honghua Zhang; Zheng Zhang; Hanfeng Guan; Zhong Fang; Feng Li
Journal:  Biomed Res Int       Date:  2019-11-19       Impact factor: 3.411

10.  SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis.

Authors:  Jie Li; Ming-Han Li; Tian-Tian Wang; Xiao-Ning Liu; Xiao-Ting Zhu; Yun-Zhang Dai; Ke-Chao Zhai; Yong-da Liu; Jia-Li Lin; Rui-Liang Ge; Shu-Han Sun; Fang Wang; Ji-Hang Yuan
Journal:  Br J Cancer       Date:  2021-07-17       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.